AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
Prescription medication is a lifeline for millions of people around the U.S. Unfortunately, the cost of such medications has ...
AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival ...
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...
WISN 12 News on MSN
Trump administration strikes deal with AbbVie to cut costs of certain drugs
The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its "Most Favored Nation" pricing initiative. Under the ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional ...
AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...
The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results